University of Arizona researchers have developed an app to assist in reducing stress and anxiety related to social isolation during the COVID-19 pandemic.

Labs and factories around the globe are racing to test and produce more than a billion doses of coronavirus vaccine. To shrink a 10-year marathon into a 10-month sprint, they are merging institutional knowledge with novel bioscience methods. "This first round of vaccines is certainly using more of what we would call experimental platforms – things that don't have a lot of track record yet," said Deepta Bhattacharya, a cell biologist and immunologist at the University of Arizona. "Now, that's not to say that it won't work. And to be honest, all of the early data that I'm seeing so far, it looks really quite promising."

As cancer care costs continue to increase in the United States, a focus on chemotherapy stewardship may result in cost savings for health systems and patients. During a session of the Hematology/Oncology Pharmacy Association Practice Management 2020 Virtual Learning Event, presenter Ali McBride, clinical coordinator of hematology/oncology for the University of Arizona Cancer Center, said a 2011 projection by the National Cancer Institute estimated there would be 18.1 million cancer survivors in the United States in 2020, which represents a 30% increase in the number of cancer survivors since 2010.

By the end of the month, tens of thousands of rapid-response antigen tests will be delivered to athletic departments across the Pac-12. One school – the University of Arizona – began using the tests months ago. The university has run 25,000 Quidel tests on students, athletes, staff members and ICU patients since the spring. David Harris, who oversees the program, said the results have been impressive. "It only seems to get better the more you do it," he said.

Just over two in five Arizona adults got a flu shot last year, a number state officials are desperate to improve on before the onset of both influenza and the ongoing COVID-19 pandemic this fall. "It's difficult to tell what the response will be each year" to the call for people to get vaccinated, said Dr. Daniel Derksen, director of the University of Arizona Center for Rural Health. "You want to protect those vulnerable populations."

Continuing coverage: Efforts are underway to bring to market a vaccine for a fungal infection that occurs in the deserts of the Southwest. With recent studies showing promise, there is a renewed push. Dr. John Galgiani, director of the University of Arizona's Valley Fever Center for Excellence, is heading up vaccine research there and believes the vaccine shown to prevent valley fever in mice should be available for dogs, which also get infected in large numbers, as soon as next year. A veterinary vaccine company, Anivive, is developing it. "It's very promising," said Galgiani.

Efforts to keep patients safe in the time of COVID-19 led to significant savings and innovation in chemotherapy delivery and earned University of Arizona Health Sciences center national recognition.

Joining the University of Arizona Health Sciences in October, Dr. Geoffrey Rubin holds six U.S. patents for medical image analysis and is past chairman of radiology at Duke University School of Medicine.

University of Arizona President Robert C. Robbins said the university expected to see an increase in COVID-19 cases, but it has become too much, necessitating a shelter-in-place recommendation similar to what the state faced in the spring.